Ovid Therapeutics Inc - Asset Resilience Ratio
Ovid Therapeutics Inc (OVID) has an Asset Resilience Ratio of 37.42% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Ovid Therapeutics Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Ovid Therapeutics Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Ovid Therapeutics Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ovid Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Ovid Therapeutics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $56.48 Million | 37.42% |
| Total Liquid Assets | $56.48 Million | 37.42% |
Asset Resilience Insights
- Very High Liquidity: Ovid Therapeutics Inc maintains exceptional liquid asset reserves at 37.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ovid Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Ovid Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Ovid Therapeutics Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Ovid Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.42% | $56.48 Million | $150.93 Million | +8.37pp |
| 2024-12-31 | 29.05% | $26.77 Million | $92.17 Million | -25.66pp |
| 2023-12-31 | 54.71% | $78.79 Million | $144.03 Million | +0.52pp |
| 2022-12-31 | 54.19% | $84.13 Million | $155.27 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $194.54 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $75.93 Million | -- |
| 2019-12-31 | 43.10% | $34.84 Million | $80.84 Million | +32.58pp |
| 2018-12-31 | 10.52% | $5.01 Million | $47.65 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $89.46 Million | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more